Journal of Sciences, Islamic Republic of Iran

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients

Document Type : Original Paper

Authors

1 1 Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. 2 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran

2 2 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. 3 Medical Genetic Research and Clinical Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Islamic Republic of Iran

3 2 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. 4 Department of Hematology and Medical Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran

4 5 Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences,Yazd, Islamic Republic of Iran

5 2 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran

6 1 Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. 6 Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. 7 Medical Genetics Research Center of Genome, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran

Abstract

       Imatinib introduction caused to improve the clinical outcomes of chronic myeloid leukemia (CML) patients. Despite the significant effects of Imatinib, pharmacogenetic variables induced treatment resistant is also observed. Imatinib is known as a P-glycoprotein (P-gp) efflux pump substrate encoded by the ABCB1 gene. The ABCB1 C1236T, G2677T/A and C3435T variants are possibly correlated with interindividual variation in pharmacokinetic response to Imatinib therapy. The present study aimed to examine the effect of ABCB1 gene variants on the therapeutic response of Imatinib in CML patients. Sixty-nine Iranian CML patients treated with Imatinib or Nilotinib were selected and divided into two groups of sensitive and resistant to Imatinib. C1236T and G2677T/A variants were genotyped by high resolution melting (HRM) analysis, and C3435T variant was genotyped using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). Then, the results were compared between the two groups of patients. Our results showed that there were no significant differences between C1236T, G2677T/A and C3435T variants of ABCB1 gene and clinical response to Imatinib in the Iranian CML patients. According to the results of this study, genotyping of ABCB1 C1236T, G2677T/A and C3435T variants couldn’t help to predict the outcomes of Imatinib treatment in CML patients. So, these variants are not useful to make decisions about treatment, but it is suggested to do further investigations.

Keywords

References
  1. Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2017;31(1):75-82. DOI: 10.1038/leu.2016.179.
  2. Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94 Suppl 2:S107-21. DOI: 10.1007/s00277-015-2325-z.
  3. Ben Hassine I, Gharbi H, Soltani I, Ben Hadj Othman H, Farrah A, Amouri H, et al. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. Cancer Chemoth Pharm. 2017;80(4):829-39. DOI: 10.1007/s00280-017-3424-4.
  4. Maia RC, Vasconcelos FC, Souza PS, Rumjanek VM. Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia. Molecules. 2018;23(1). DOI: 10.3390/molecules23010119.
  5. Lardo M, Castro M, Moiraghi B, Rojas F, Borda N, Rey JA, et al. MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Res. 2015;50(3):154-9. DOI: 10.5045/br.2015.50.3.154.
  6. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3:47. DOI: 10.1186/1756-8722-3-47.
  7. Eadie LN, Hughes TP, White DL. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. Plos one. 2016;11(8):e0161470. DOI: 10.1371/journal.pone.0161470.
  8. Ankathil R, Azlan H, Dzarr AA, Baba AA. Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics. 2018;19(5):475-393. DOI: 10.2217/pgs-2017-0193.
  9. Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, et al. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother. 2014;68(3):343-9. DOI: 10.1016/j.biopha.2014.01.009.
  10. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525-8. DOI: 10.1126/science.1135308.
  11. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112(5):2024-7. DOI: 10.1182/blood-2008-03-147744.
  12. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28(1):265-9. DOI: 10.1007/s12032-010-9456-9.
  13. Maffioli M, Camós M, Gaya A, Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leukemia Res. 2011;35(8):1014-9. DOI: 10.1016/j.leukres.2010.12.004.
  14. Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55(11):731-7. DOI: 10.1038/jhg.2010.98.
  15. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(14):4750-8. DOI: 10.1158/1078-0432.CCR-09-0145.
  16. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol. 2013;24(3):756-60. DOI: 10.1093/annonc/mds532 .
  17. Zheng Q, Wu H, Yu Q, Kim DH, Lipton JH, Angelini S, et al. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015;15(2):127-34. DOI: 10.1038/tpj.2014.54.
  18. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013;98(2):193-200. DOI: 10.3324/haematol.2012.066480.
  19. Polillo M, Galimberti S, Baratè C, Petrini M, Danesi R, Di Paolo A. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. Int J Mol Sci. 2015;16(9):22811-29. DOI: 10.3390/ijms160922811.
  20. Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GK, Barros LS, et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett. 2014;7(4):1313-9. DOI: 10.3892/ol.2014.1857.
  21. Glady L, Guerin E, Ame S, Maloisel F, Lessinger JM. A single-nucleotide polymorphism of ABCB1 (MDR1) is correlated with poor response to Imatinib chronic myeloid leukemia. Ann Oncol. 2017;28:2. DOI: 10.1093/annonc/mdx508.009.
  22. Deenik W, van der Holt B, Janssen J, Chu IWT, Valk PJM, Ossenkoppele GJ, et al. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood. 2010;116(26):6144-5. DOI: 10.1182/blood-2010-07-296954.
  23. Ali MA, Elsalakawy WA. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med Oncol. 2014;31(11):279. DOI: 10.1007/s12032-014-0279-y.
  24. Belohlavkova P, Vrbacky F, Voglova J, Racil Z, Zackova D, Hrochova K, et al. The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Arch Med Sci. 2018;14(6):1416-23. DOI: 10.5114/aoms.2018.73538.
  25. Rinaldi I, Nova R, Widyastuti R, Priambodo R, Instiaty I, Louisa M. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients. Asian Pac J Cancer Prev. 2019;20(11):3331-4. DOI: 10.31557/APJCP.2019.20.11.3331.
  26. Mohammadi F, Shafiei M, Assad D, Rostami G, Hamid M, Foroughmand AM. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response. Iran Biomed J. 2021; 25(1):54-61. DOI: 10.29252/ibj.25.1.54.
  27. Saidijam M, Mahjub H, Shabab N, Yadegarazari R. Simultaneous analysis of multidrug resistance 1(MDR1) C3435T, G2677T/A, and C1236T genotypes in Hamadan City population, West of Iran. Iran Biomed J. 2015;19(1):57-62. DOI: 10.6091/ibj.1381.2014.
  28. Kassogue Y, Dehbi H, Quachouh M, Quessar A, Benchekroun S, Nadifi S. Lack of Association of Multidrug Resistance Gene-1 Polymorphisms with Treatment Outcome in Chronic Myeloid Leukemia Patients Treated with Imatinib. Middle East J Cancer. 2015;6(4):229-35.
  29. Yaya K, Hind D, Meryem Q, Asma Q, Said B, Sellama N. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. Tumour Biol. 2014;35(11):10969-75. DOI: 10.1007/s13277-014-2400-4.
  30. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8. DOI: 10.1200/JCO.2009.26.3087. 
  31. Dulucq S, Preudhomme C, Guilhot F, Mahon FX. Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood. 2010;116(26):6145-6. DOI: 10.1182/blood-2010-08-298794.  

 
  1. Vivona D, Bueno CT, Lima LT, Hirata RD, Hirata MH, Luchessi AD, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012;48(2):132-6. DOI: 10.1016/j.bcmd.2011.11.001.
  2. Zu BL, Li YJ, Wang X, He DL, Huang ZL, Feng WL. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2014;15(5):667-77. DOI: 10.2217/pgs.13.222.
  3. Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 2014;19(3):123-8. DOI: 10.1179/1607845413Y.0000000102.
  4. Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi NA. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol. 2016;37(1):791-8. DOI: 10.1007/s13277-015-3874-4.
Journal of Sciences, Islamic Republic of Iran
Volume 32, Issue 2
May 2021
Pages 121-130
Files
Share
How to cite
Statistics